Monoclonal VLR antibody discovery and engineering: We provide access to NovAb’s VLR monoclonal antibody technology through technology transfer/licensing and product discovery transfer/licensing arrangements. These usually consist of:

1. Immunogen (target) preparation, which can be done by our partner or NovAb
2. Lamprey immunizations, done by NovAb
3. Immune sera and lymphocyte preparations and assays of immune lamprey sera, done by NovAb
4. Preparation of VLR antibody libraries, e.g., VLR yeast display libraries, done by NovAb
5. VLR library selections, which can be done by NovAb, our partner, or both, i.e., we transfer the VLR libraries to partner along with positive and negative control VLR antibodies, reagents, and protocols
6. Determination of VLR sequences and binding characterization of positive VLR library clones, which may be done by NovAb, our partner, or both
7. Expression of positive VLR antibodies usually as VLR IgG Fc fusion proteins but other forms are also available, which may be done by NovAb, our partner, or both
8. Further functional characterization of the selected VLR antibodies, usually done by our partner
9. VLR antibody engineering, e.g., bispecific VLR antibodies and VLR antibody polymers, which may be done by NovAb or our partner. Commercialization of VLR antibodies will require a license from NovAb, which may be nonexclusive, exclusive, co-exclusive, or limited time exclusive, i.e., exclusive for 1 to 3 years then nonexclusive.

We also form collaborative partnerships for access to NovAb’s multimeric ligand technology. These typically utilize ligands from our partner to construct multimeric ligand compositions that are then transferred to our partners to support their research and development activities.